Scarica l'app Stockscreener
29.96
1.12%
-0.34
Dopo l'orario di chiusura:
29.96
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$30.30
Aprire:
$30.27
Volume 24 ore:
1.34M
Relative Volume:
0.72
Capitalizzazione di mercato:
$2.89B
Reddito:
$522.75M
Utile/perdita netta:
$-558.99M
Rapporto P/E:
-4.6306
EPS:
-6.47
Flusso di cassa netto:
$-439.53M
1 W Prestazione:
+0.60%
1M Prestazione:
+8.32%
6M Prestazione:
-28.62%
1 anno Prestazione:
-47.40%
Intervallo 1D:
$29.71
$30.60
Intervallo di 1 settimana:
$29.04
$30.61
Portata 52W:
$25.81
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Nome
Ultragenyx Pharmaceutical Inc
Settore
Industria
Telefono
415-483-8800
Indirizzo
60 LEVERONI COURT, NOVATO, CA
Confronta RARE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
29.96 | 2.92B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-28 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-28 | Iniziato | William Blair | Outperform |
| 2024-06-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-04-22 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-06-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-12-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-03 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-08-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-19 | Iniziato | UBS | Sell |
| 2021-07-15 | Iniziato | Guggenheim | Neutral |
| 2021-06-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-05-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-05-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-02 | Ripresa | Stifel | Buy |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-11-24 | Ripresa | Evercore ISI | In-line |
| 2020-11-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2019-08-02 | Ripresa | Wedbush | Outperform |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Iniziato | Goldman | Neutral |
| 2018-04-18 | Aggiornamento | SunTrust | Hold → Buy |
| 2018-03-22 | Ripresa | Piper Jaffray | Overweight |
| 2018-02-21 | Reiterato | Stifel | Buy |
| 2018-01-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Iniziato | Credit Suisse | Outperform |
| 2017-12-05 | Reiterato | Barclays | Equal Weight |
| 2017-12-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-09-14 | Aggiornamento | Wedbush | Neutral → Outperform |
Mostra tutto
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
Ultragenyx Pharmaceutical Inc. stock daily chart insightsWeekly Trend Recap & Free Weekly Watchlist of Top Performers - Newser
Real time pattern detection on Ultragenyx Pharmaceutical Inc. stock2025 Biggest Moves & Weekly Watchlist for Hot Stocks - Newser
What earnings revisions data tells us about Ultragenyx Pharmaceutical Inc.Weekly Trade Recap & Scalable Portfolio Growth Methods - Newser
Does Ultragenyx Pharmaceutical Inc. outperform in volatile marketsJuly 2025 Market Mood & High Accuracy Trade Alerts - خودرو بانک
Full technical analysis of Ultragenyx Pharmaceutical Inc. stock2025 Market Outlook & Expert Curated Trade Setups - Newser
Published on: 2025-09-01 02:49:16 - Newser
Published on: 2025-08-31 23:35:05 - Newser
What does recent volatility data suggest for Ultragenyx Pharmaceutical Inc.2025 Earnings Surprises & Proven Capital Preservation Methods - Newser
Ultragenyx Pharmaceutical Inc. stock trendline breakdownJuly 2025 Selloffs & Accurate Technical Buy Alerts - Newser
Ultragenyx Pharmaceutical Inc. stock trend forecastMarket Sentiment Summary & Fast Momentum Stock Entry Tips - Newser
How to build a dashboard for Ultragenyx Pharmaceutical Inc. stock2025 Trading Volume Trends & Daily Stock Trend Watchlist - Newser
Applying sector rotation models to Ultragenyx Pharmaceutical Inc.Insider Selling & Daily Chart Pattern Signal Reports - Newser
Ultragenyx Pharmaceutical Inc. stock outlook for YEARJuly 2025 Update & High Accuracy Trade Alerts - Newser
Quantitative breakdown of Ultragenyx Pharmaceutical Inc. recent moveRate Cut & Low Drawdown Momentum Trade Ideas - Newser
Custom watchlist performance reports with Ultragenyx Pharmaceutical Inc.M&A Rumor & AI Driven Price Forecasts - Newser
Trend analysis for Ultragenyx Pharmaceutical Inc. this weekJuly 2025 Update & Fast Exit Strategy with Risk Control - Newser
Ultragenyx Pharmaceutical Inc. recovery potential after sell offCEO Change & Verified Short-Term Plans - Newser
How hedge fund analytics apply to Ultragenyx Pharmaceutical Inc. stockJuly 2025 Price Swings & High Return Trade Guides - Newser
Applying big data sentiment scoring on Ultragenyx Pharmaceutical Inc.Quarterly Growth Report & AI Forecast Swing Trade Picks - Newser
Intraday pattern recognizer results for Ultragenyx Pharmaceutical Inc.2025 Bull vs Bear & Safe Swing Trade Setups - Newser
News impact scoring models applied to Ultragenyx Pharmaceutical Inc.Weekly Trade Report & Safe Capital Growth Trade Ideas - Newser
Published on: 2025-08-31 00:07:10 - Newser
Top chart patterns to watch in Ultragenyx Pharmaceutical Inc.Forecast Cut & Advanced Swing Trade Entry Plans - Newser
How to interpret RSI for Ultragenyx Pharmaceutical Inc. stockJuly 2025 Final Week & Growth-Oriented Investment Plans - Newser
Will Ultragenyx Pharmaceutical Inc. stock recover after recent dropPortfolio Value Report & Free Accurate Trade Setup Notifications - Newser
What Fibonacci levels say about Ultragenyx Pharmaceutical Inc. rebound2025 Trading Recap & Daily Entry Point Trade Alerts - Newser
Signal strength of Ultragenyx Pharmaceutical Inc. stock in tech scannersJuly 2025 Big Picture & Accurate Intraday Trading Signals - Newser
Ultragenyx Pharmaceutical Inc. stock momentum explainedGap Down & Weekly High Return Forecasts - Newser
Published on: 2025-08-30 07:57:48 - Newser
Ultragenyx Pharmaceutical Inc Azioni (RARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.96%
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):